-
FDA Approves Omcazio: A New Cabozantinib Formulation for Flexible Dosing
A New Milestone in Oncology Treatment The landscape of cancer treatment continues to evolve, and the FDA has recently reached a new milestone with the approval of Omcazio. This new oral formulation of cabozantinib is designed to offer patients and healthcare providers greater flexibility in their treatment regimen. Key Advantages of Omcazio The most significant…